IN Brief:
- The recall covers 63,078 units across three batches of a2 Platinum Premium infant formula.
- An estimated 16,428 units were sold through a2MC’s website, Amazon, and Meijer.
- Cereulide is heat-stable, making ingredient control and upstream quality assurance central to risk management.
The a2 Milk Company has recalled three US batches of a2 Platinum Premium infant formula after testing detected cereulide, a toxin associated with Bacillus cereus.
The recall covers 63,078 units of a2 Platinum Premium infant formula for infants aged 0 to 12 months, packaged in 31.7oz tins. An estimated 16,428 units were sold to consumers. The affected batch numbers are 2210269454, with a use-by date of 15 July 2026; 2210324609, with a use-by date of 21 January 2027; and 2210321712, with a use-by date of 15 January 2027.
The product was distributed nationally through a2MC’s website, Amazon, and Meijer stores as part of Operation Fly Formula. Importation rights expired on 31 December 2025, and the product had been discontinued and removed from sale before the recall was initiated. No confirmed illnesses or harm have been reported.
The recall was initiated after cereulide was detected through additional testing carried out in response to new guidance from New Zealand’s food regulatory authority. The probable source of the cereulide is an ingredient in the product. The recall is being carried out with the knowledge of the US Food and Drug Administration.
Cereulide can cause gastrointestinal symptoms including nausea and vomiting, typically developing between 30 minutes and six hours after ingestion and often resolving within 24 hours. Infants are at greater risk because of developing immune systems and the potential for complications such as dehydration. Consumers with affected tins have been advised not to use the product and to dispose of it or return it for a refund.
The case is notable because cereulide is heat-stable. Consumer preparation with hot water cannot be relied on to remove the hazard once the toxin is present. The relevant control point sits earlier in the chain, across ingredient quality, supplier assurance, environmental monitoring, testing regimes, and process conditions before product release.
Infant formula is one of the most scrutinised food categories because the consumer group is highly vulnerable and the products are often used as a primary source of nutrition. Recalls in the category tend to raise wider questions about manufacturing controls, ingredient sourcing, and cross-border regulatory alignment. In this case, additional testing was linked to regulatory guidance from New Zealand, while the affected product was sold in the US.
The ingredient link is central. Formula manufacturing depends on complex dry ingredient systems, and hazards in powders can be difficult to manage once they enter the production stream. Heat treatment at an earlier stage can reduce microbial risk, but heat-stable toxins require prevention rather than correction. Supplier controls, raw-material testing, batch traceability, and rapid recall execution become critical.
The recall is limited in volume compared with the global infant formula market, but the operational lessons are broader. Manufacturers of powdered foods face increasing pressure to show that food safety systems account for pathogens, toxins, ingredient history, and evolving regulatory guidance. In dry dairy and nutrition products, control of low-moisture environments, validated sanitation, and ingredient verification remain essential.
The immediate priority is removal of affected product from consumers and distribution channels. Across powdered nutrition manufacturing, the case reinforces the role of ingredient assurance before final blending and packing.
